Company Overview
Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States. It delivers customized healthcare experience to meet the needs of seniors through its Medicare Advantage plans. Alignment Healthcare, Inc. was founded in 2013 and is based in Orange, California.
Why Investors Should Care
Net profit has compounded at 33.2% per year over the last five years.
Revenue has grown at a 40.2% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.95B (+46.1% YoY); net profit $-724.00K.
- Trailing 12 Months Year-on-year growth — revenue +33.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 40.2%, profit CAGR 33.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 40.16% |
| 1 Year: | 33.30% |
Compounded Profit Growth
| 5 Years: | 33.17% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +58.21% |
| 6 Months: | +2.02% |
| 3 Months: | +1.05% |
| 1 Month: | +4.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Death Cross4d ago
- RSI (14)51.30 · Neutral
P/E of 212.00 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 40.2% over 5 years.
- Profit CAGR of 33.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 212.0.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALHC Alignment Healthcare, Inc. R2K | 21.20 | 212.00 | $4.38B | 0.00% | 2.92% | 12.53% | 40.16% | 33.17% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 224.27M | 243.96M | 245.49M | 267.00M | 308.74M | 293.27M | 345.29M | 366.18M | 359.98M | 434.81M | 456.88M | 450.24M | - | - | - | - | 926.93M | 1.02B | 993.70M | 1.01B | 1.24B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 820.90M | 881.74M | 868.02M | 889.49M | 1.09B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 106.03M | 133.55M | 125.67M | 123.31M | 144.48M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.42M | 110.80M | 117.99M | 133.59M | 128.98M |
| Operating Income | -5.12M | 12.59M | 15.06M | -52.66M | -40.49M | -41.45M | -36.48M | -6.65M | -33.41M | -32.49M | -23.66M | -29.76M | -41.11M | -18.38M | - | - | -5.39M | 22.75M | 7.68M | -10.28M | 15.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.24M | 29.86M | 15.67M | -2.45M | 23.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.95M | 3.95M | 3.95M | 3.95M | 4.06M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.33M | 18.88M | 3.73M | -14.23M | 11.44M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.00K | 3.22M | 2.00K | -3.23M | 25.00K |
| Net Income | -10.07M | 8.37M | 10.85M | -56.87M | -44.76M | -45.82M | -40.82M | -11.58M | -40.25M | -37.28M | -28.48M | -35.05M | -46.52M | -24.01M | - | - | -9.11M | 15.67M | 3.73M | -11.01M | 11.42M |
| Diluted EPS | - | - | - | - | -0.25 | -0.26 | -0.23 | -0.06 | -0.22 | -0.20 | -0.15 | -0.19 | -0.25 | -0.13 | - | - | -0.05 | 0.07 | 0.02 | -0.05 | 0.05 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 753.97M | 955.39M | 1.17B | 1.43B | 1.82B | 2.70B | 3.95B |
| Cost of Revenue | - | - | - | 1.25B | 1.62B | 2.41B | 3.46B |
| Gross Profit | - | - | - | 184.28M | 201.03M | 296.69M | 488.56M |
| Operating Expenses | - | - | - | 312.92M | 328.85M | 398.25M | 473.81M |
| Operating Income | -29.48M | -5.26M | -178.07M | -128.64M | -127.82M | -101.56M | 14.75M |
| EBITDA | - | - | - | -113.53M | -105.30M | -77.44M | 45.32M |
| Interest Expense | - | - | - | 18.29M | 21.23M | 23.55M | 15.80M |
| Pretax Income | - | - | - | -149.30M | -148.19M | -128.05M | -958.00K |
| Tax Provision | - | - | - | 339.00K | -22.00K | 21.00K | 20.00K |
| Net Income | -44.73M | -22.93M | -195.29M | -149.55M | -148.02M | -128.03M | -724.00K |
| Diluted EPS | - | -0.15 | -1.14 | -0.83 | -0.79 | -0.67 | 0.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 338.50M | - | 633.86M | 591.88M | 782.06M | 1.07B |
| Current Assets | - | - | - | - | 544.55M | 483.54M | 661.64M | 951.58M |
| Cash & Equivalents | - | 86.48M | 207.31M | - | 409.55M | 202.90M | 432.86M | 575.82M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 92.89M | 119.75M | 153.90M | 253.21M |
| Total Liabilities | - | - | 307.89M | - | 394.56M | 433.81M | 681.11M | 886.51M |
| Current Liabilities | - | - | 153.45M | - | 229.96M | 263.02M | 351.85M | 556.87M |
| Long Term Debt | - | - | 144.17M | - | 160.90M | 161.81M | 321.43M | 323.18M |
| Total Debt | - | - | - | - | 164.60M | 170.79M | 329.26M | 329.64M |
| Total Equity | -33.66M | -78.71M | 30.61M | - | 238.13M | 156.95M | 99.85M | 179.28M |
| Shares Outstanding | - | - | - | - | 187.28M | 188.95M | 191.78M | 204.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 9.21M | 7.56M | - | -45.43M | -59.19M | 34.77M | 139.93M |
| Investing Cash Flow | -10.24M | -16.36M | - | -28.22M | -147.26M | 39.19M | -14.97M |
| Financing Cash Flow | 52.66M | 130.12M | - | 16.59M | 105.00K | 156.03M | 18.04M |
| Capital Expenditure | - | - | - | -23.77M | -35.99M | -41.42M | -26.78M |
| Free Cash Flow | - | - | - | -69.20M | -95.18M | -6.65M | 113.15M |
| Net Change in Cash | - | - | - | -57.05M | -206.34M | 229.99M | 142.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 12.8% | 11.0% | 11.0% | 12.4% |
| Operating Margin % | -3.9% | -0.6% | -15.3% | -9.0% | -7.0% | -3.8% | 0.4% |
| Net Margin % | -5.9% | -2.4% | -16.7% | -10.4% | -8.1% | -4.7% | -0.0% |
| ROE % | 56.8% | -74.9% | - | -62.8% | -94.3% | -128.2% | -0.4% |
| ROCE % | - | -2.8% | - | -31.8% | -38.9% | -23.6% | 2.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wellington Management Group, LLP | 8.27% | 17.10M | $418.67M |
| 2 | FMR, LLC | 7.69% | 15.89M | $389.12M |
| 3 | Blackrock Inc. | 6.81% | 14.08M | $344.63M |
| 4 | T. Rowe Price Investment Management, Inc. | 6.36% | 13.15M | $321.92M |
| 5 | Vanguard Portfolio Management LLC | 4.70% | 9.71M | $237.75M |
| 6 | Vanguard Capital Management LLC | 3.86% | 7.97M | $195.24M |
| 7 | Invesco Ltd. | 3.39% | 7.00M | $171.40M |
| 8 | Hood River Capital Management LLC | 2.93% | 6.05M | $148.24M |
| 9 | Price (T.Rowe) Associates Inc | 2.78% | 5.74M | $140.58M |
| 10 | Citadel Advisors Llc | 2.59% | 5.36M | $131.30M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALHC
PACS or ALHC: Which Is the Better Value Stock Right Now?
PACS vs. ALHC: Which Stock Is the Better Value Option?
‘The system is undeniably broken’: More insurers sue CMS over Medicare Advantage stars
SCAN Health Plan and Alignment Healthcare both filed lawsuits against the CMS last week after regulators refused to recalculate industry-wide MA scores using the same methodology as for Clover Health.…
This Medicare Advantage Stock Is Shrugging Off a Whistleblower Lawsuit
Alignment Healthcare shares rose Thursday, with one analyst saying a selloff after a whistleblower lawsuit was “overdone.”
Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
ORANGE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its second quarter 2026 financial results on Thursday, July 30, 2026, after market close. Following the release, the company will host…
Whistleblower lawsuit accuses Alignment of accounting fraud
A former executive is claiming that the MA insurer recorded millions of dollars as capital expenditures that should have been operating expenses, inflating its value. Alignment strongly denied the allegations.…
ALHC Stock Clocks Worst Day In Over 2 Years On Whistleblower Financial Manipulation Allegation
Hakan Kardes claims in the suit filed in the U.S. District Court for the Central District of California that the company forced him to resign after he reported alleged accounting fraud to other executives.…
ALHC — Frequently Asked Questions
What is the current share price of Alignment Healthcare, Inc. (ALHC)?
As of 2026-07-14 21:23 PDT, Alignment Healthcare, Inc. (ALHC) trades at $21.20 on NasdaqGS. Its 52-week range is $11.64 to $24.56.
What is the market capitalisation of ALHC?
Alignment Healthcare, Inc. (ALHC) has a market capitalisation of $4.38B on NasdaqGS.
What is the P/E ratio of ALHC?
ALHC trades at a trailing price-to-earnings (P/E) ratio of 212.00. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 19.73.
What is the return on equity (ROE) of ALHC?
ALHC has a return on equity (ROE) of 12.53%. Its return on capital employed (ROCE) is 2.92%.
Is ALHC a good stock to buy?
This page provides a data-driven analysis of Alignment Healthcare, Inc. (ALHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.